Celldex Therapeutics (CLDX) Asset Writedowns and Impairment (2017 - 2021)

Celldex Therapeutics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $3.5 million for Q3 2021.

• In Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $3.5 million; the TTM figure through Sep 2021 stood at $21.5 million (changed N/A YoY), while the FY2021 annual figure was $3.5 million, down 80.56% from the prior year.
• Asset Writedowns and Impairment was $3.5 million for Q3 2021 at Celldex Therapeutics, down from $14.5 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $14.5 million in Q4 2020 to a low of $1.8 million in Q1 2019.
• Historically, Asset Writedowns and Impairment has averaged $7.9 million across 5 years, with a median of $6.9 million in 2018.
• Biggest YoY gain for Asset Writedowns and Impairment was 84.75% in 2019; the steepest drop was 84.75% in 2019.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $13.0 million in 2017, then slumped by 47.1% to $6.9 million in 2018, then tumbled by 73.83% to $1.8 million in 2019, then soared by 705.56% to $14.5 million in 2020, then sank by 75.86% to $3.5 million in 2021.
• The last three Asset Writedowns and Impairment figures came in at $3.5 million (Q3 2021), $14.5 million (Q4 2020), and $3.5 million (Q2 2020), per Business Quant data.